Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CORT Corcept Therapeutics	$71.68 -7.6%	$72.82	$28.04 ▼ $117.33	$7.60B	0.22	1.14 million shs	6.06 million shs
JAZZ Jazz Pharmaceuticals	$108.29 +0.2%	$109.27	$95.49 ▼ $148.06	$6.68B	0.38	836,358 shs	1.03 million shs
PRVB Provention Bio	$24.98	$24.58	$3.18 ▼ $25.00	$2.37B	2.47	2.28 million shs	218,200 shs
ROIV Roivant Sciences	$11.17 +1.6%	$10.55	$8.73 ▼ $13.06	$7.97B	1.23	5.53 million shs	7.58 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CORT Corcept Therapeutics	-8.21%	-8.91%	-1.50%	+28.02%	+137.59%
JAZZ Jazz Pharmaceuticals	+0.01%	+0.20%	-9.80%	-22.07%	+2.89%
PRVB Provention Bio	0.00%	0.00%	0.00%	0.00%	0.00%
ROIV Roivant Sciences	+1.73%	+2.76%	-2.70%	+8.24%	+7.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CORT Corcept Therapeutics	4.7051 of 5 stars	3.5	3.0	0.0	4.2	2.1	4.2	1.9
JAZZ Jazz Pharmaceuticals	4.8873 of 5 stars	4.5	1.0	0.0	4.0	2.1	3.3	3.1
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	2.2786 of 5 stars	3.5	3.0	0.0	0.0	1.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CORT Corcept Therapeutics	3.00	Buy	$138.25	92.87% Upside
JAZZ Jazz Pharmaceuticals	2.93	Moderate Buy	$182.79	68.79% Upside
PRVB Provention Bio	0.00	N/A	N/A	N/A
ROIV Roivant Sciences	3.00	Buy	$17.50	56.67% Upside

Current Analyst Ratings Breakdown

Latest PRVB, CORT, ROIV, and JAZZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$182.00 ➝ $172.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$167.00 ➝ $155.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$176.00 ➝ $147.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$183.00 ➝ $166.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$200.00 ➝ $200.00
5/6/2025	CORT Corcept Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$135.00
5/6/2025	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00
4/21/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/10/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$210.00 ➝ $210.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CORT Corcept Therapeutics	$685.45M	11.09	$1.05 per share	67.96	$4.92 per share	14.57
JAZZ Jazz Pharmaceuticals	$4.06B	1.64	$22.05 per share	4.91	$59.36 per share	1.82
PRVB Provention Bio	$12.90M	183.54	N/A	N/A	$1.40 per share	17.84
ROIV Roivant Sciences	$29.05M	274.34	N/A	N/A	$7.76 per share	1.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CORT Corcept Therapeutics	$106.14M	$1.16	56.89	38.75	N/A	22.35%	24.54%	20.24%	7/28/2025 (Estimated)
JAZZ Jazz Pharmaceuticals	$414.83M	$7.50	15.25	5.79	1.04	11.60%	29.30%	9.72%	7/30/2025 (Estimated)
PRVB Provention Bio	-$113.57M	-$1.53	N/A	N/A	N/A	-880.69%	-103.36%	-69.08%	N/A
ROIV Roivant Sciences	$4.35B	-$0.25	N/A	N/A	N/A	-119.54%	-14.05%	-12.81%	8/6/2025 (Estimated)

Latest PRVB, CORT, ROIV, and JAZZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/6/2025	Q1 2025	JAZZ Jazz Pharmaceuticals	$4.65	$1.68	-$2.97	-$1.52	$984.16 million	$897.84 million
5/5/2025	Q1 2025	CORT Corcept Therapeutics	$0.17	$0.17	N/A	$0.17	$177.93 million	$157.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CORT Corcept Therapeutics	0.01	3.70	3.64
JAZZ Jazz Pharmaceuticals	1.46	4.26	3.74
PRVB Provention Bio	0.19	1.93	1.92
ROIV Roivant Sciences	N/A	37.91	37.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CORT Corcept Therapeutics	93.61%
JAZZ Jazz Pharmaceuticals	89.14%
PRVB Provention Bio	37.39%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
CORT Corcept Therapeutics	20.80%
JAZZ Jazz Pharmaceuticals	4.20%
PRVB Provention Bio	13.10%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CORT Corcept Therapeutics	300	106.05 million	83.30 million	Optionable
JAZZ Jazz Pharmaceuticals	3,200	61.65 million	57.92 million	Optionable
PRVB Provention Bio	82	94.78 million	82.37 million	Not Optionable
ROIV Roivant Sciences	860	713.55 million	657.18 million	Optionable

PRVB, CORT, ROIV, and JAZZ Headlines

Recent News About These Companies

Jefferies Financial Group Inc. Makes New Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 1 at 4:45 AM | marketbeat.com

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 1 at 3:37 AM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Trading 5.5% Higher - Here's Why

May 30, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPS

May 30, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript

May 30, 2025 | insidermonkey.com

What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings

May 30, 2025 | finance.yahoo.com

Why Roivant Sciences Ltd. (ROIV) Surged On Thursday

May 30, 2025 | msn.com

Roivant Sciences (NASDAQ:ROIV) Given "Buy" Rating at HC Wainwright

May 30, 2025 | americanbankingnews.com

Roivant Sciences Reports Progress and Financial Results

May 30, 2025 | tipranks.com

H.C. Wainwright maintains $18 target on Roivant Sciences stock

May 29, 2025 | investing.com

Roivant Sciences Earnings Call: Balancing Growth and Challenges

May 29, 2025 | tipranks.com

Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript

May 29, 2025 | seekingalpha.com

Roivant Sciences Ltd. 2024 Q4 - Results - Earnings Call Presentation

May 29, 2025 | seekingalpha.com

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates

May 29, 2025 | zacks.com

Roivant Sciences' (ROIV) Buy Rating Reaffirmed at HC Wainwright

May 29, 2025 | marketbeat.com

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 29, 2025 | globenewswire.com

H.C. Wainwright maintient son objectif de 18€ pour l’action Roivant Sciences

May 28, 2025 | fr.investing.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

May 28, 2025 | marketbeat.com

Roivant Sciences (ROIV) to Release Earnings on Thursday

May 27, 2025 | americanbankingnews.com

Roivant Sciences (ROIV) Projected to Post Quarterly Earnings on Thursday

May 24, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares

May 23, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRVB, CORT, ROIV, and JAZZ Company Descriptions

Corcept Therapeutics NASDAQ:CORT

$71.68 -5.88 (-7.58%)

Closing price 06/2/2025 04:00 PM Eastern

Extended Trading

$72.75 +1.07 (+1.49%)

As of 09:23 AM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Jazz Pharmaceuticals NASDAQ:JAZZ

$108.29 +0.22 (+0.20%)

Closing price 06/2/2025 04:00 PM Eastern

Extended Trading

$109.14 +0.85 (+0.79%)

As of 09:25 AM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Provention Bio NASDAQ:PRVB

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Roivant Sciences NASDAQ:ROIV

$11.17 +0.18 (+1.64%)

Closing price 06/2/2025 04:00 PM Eastern

Extended Trading

$11.08 -0.08 (-0.76%)

As of 09:25 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time